Jubilant Pharmova’s arm inks Shareholders’ Agreement with Pierre Fabre SA

20 Mar 2025 Evaluate

Jubilant Pharmova’s step down subsidiary -- Jubilant Biosys Innovative Research Services (JBIRSPL) has executed Shareholders’ Agreement and other transition agreements with Pierre Fabre SA, and its affiliate entities (PF), and subscribed to 80% equity capital in JASMIN, with remaining 20% equity capital retained by PF. Simultaneously, the acquisition of PF’s R&D Centre (including R&D Site and R&D activities) at Saint Julien, France by JASMIN stands successfully closed. 

JASMIN is a company incorporated by PF in France, as a Societe par Actions Simplifiee (SAS). On closure of transaction, name of JASMIN has been changed to ‘Jubilant Biosys France’ which is now a subsidiary of JBIRSPL. 

JBIRSPL is a subsidiary of Jubilant Biosys, a wholly owned subsidiary of the company.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.


Jubilant Pharmova Share Price

919.40 5.10 (0.56%)
22-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1747.25
Dr. Reddys Lab 1174.85
Cipla 1528.10
Lupin 2046.90
Zydus Lifesciences 852.50
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...